Harnessing the Power

of Immune Tolerance

Facilitated
Allo-HSCT Therapy

 

We are developing an innovative and proprietary method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care across numerous therapeutic areas.

With Facilitated Allo-HSCT Therapy, we aim to remove solid organ transplantation recipients’ need for chronic immunosuppression and treat patients who suffer from severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.

Learn more about our therapeutic areas:

Talaris has launched a multi-center, Phase 3 clinical trial of FCR001 in living donor kidney transplant patients, to assess the efficacy and safety of FCR001 in weaning patients off all chronic immunosuppression by twelve months post-transplant.

Freedom 1 logo white

To learn more about the study and determine if you may be eligible to participate, click here.

Clinical trial details are available here 

News

Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell...  READ MORE
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022
Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on immunosuppression after 5 years In long-term follow up of Phase 2 patients, all patients originally...  READ MORE